US Stocks Movement: Nanobiotix surged on October 27 due to clinical data on melanoma and NBTXR3
Bitget异动解读2026/10/27 19:45Interpretation of Nanobiotix's Surge on October 27
Keywords: Melanoma clinical data, NBTXR3
On October 24, 2026, Nanobiotix announced the final data from a phase I study of JNJ-1900 NBTXR3 combined with immune checkpoint inhibitors for the treatment of anti-PD-1 resistant primary cutaneous melanoma: objective response rate in 24 patients was 41.7% (10 out of 24), including 4 complete remissions; disease control rate was 75% (18 out of 24), and median overall survival was 17.8 months.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Broadcom arranges financial partners to purchase custom AI accelerator racks
Boeing plunges! 737 production target delayed until next year, free cash flow guidance significantly below market expectations | Earnings Report Update
Boeing’s CEO stated on Tuesday that the company's goal of producing 47 aircraft per month for its 737 series will be delayed until early 2027, which is significantly later than previously expected. The company anticipates about $3 billion in free cash flow next year and around $6 billion in 2028, both well below market expectations of $5.6 billion and $9.6 billion, respectively. Boeing adjusted a third-quarter loss per share of $0.34, worse than the market's forecasted $0.21 loss per share. Boeing shares fell 10% on Tuesday.
Google Cloud officially launches VMware solution
Crypto prices
More
